Novo Nordisk Goes ‘Full-Speed Ahead’ Towards Once-Weekly Basal Insulin
Readouts to all six ONWARDS trials to come in 2022, Development Head Says
Executive Summary
Novo Nordisk’s once-weekly injected basal insulin icodec could be a boon to the many people with type 2 diabetes who are reluctant to start on insulin therapy due to the need for daily injections, the Danish group’s head of development tells Scrip.
You may also be interested in...
Novo Nordisk’s Once-Weekly Insulin Gains Superiority Finding As Lilly Advances
The ONWARDS 1 and 6 results closely follow success in ONWARDS 2 in April, further helping strengthen insulin icodec’s potential market position, but Lilly is nipping at Novo’s heels.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.